No, doses above the therapeutic maximum typically result in more side effects without additional benefit. For example, the VA NEPHRON D study showed increased rates of hyperkalemia and AKI with dual RAAS blockade. We now have more medication options to reduce proteinuria including SGLT2-INHs and fin...